Participant Perspectives and Experiences Following an Intensively Monitored Antiretroviral Pause (IMAP) in the United States: Results from the AIDS Clinical Trials Group (ACTG) A5345 Biomarker Study.

Dube K, Eskaf S, Barr L, Palm D, Hogg E, Simoni J, Sugarman J, Brown B, Sauceda JA, Henley L, Deeks SG, Fox L, Gandhi R, Smith DM, Li J. Participant Perspectives and Experiences Following an Intensively Monitored Antiretroviral Pause (IMAP) in the United States: Results from the AIDS Clinical Trials Group (ACTG) A5345 Biomarker Study. AIDS research and human retroviruses. 2022 Mar 24. PMID: 35323030 [PubMed]

Abstract

The AIDS Clinical Trials Group (ACTG) A5345 study (NCT03001128) included an intensively monitored antiretroviral pause (IMAP), during which participants living with HIV temporarily stopped antiretroviral treatment (ART) in an effort to identify biomarkers that could predict HIV rebound. We evaluated the potential impact of the IMAP on A5345 study participants in the United States by questioning them immediately after the IMAP and at the end of the study.